The results of a new study indicate Adalimumab, an anti-tumor necrosis factor antibody, is effective in maintaining remission in certain children with Crohn's disease, according to a news release.
The study was published in Gastroenterology, the journal of the American Gastroenterological Association.
This study, the largest double-blind study of an anti-TNF agent in children with Crohn's disease, found that more than 80 percent of children with moderate to severe Crohn's disease responded to the therapy within a month. By six months, about 34 percent of patients were in clinical remission, and after a year, more than 28 percent were in remission.
Related Articles on the American Gastroenterological Association:
Study: Aspirin Reduces Risk of Barrett's Esophagus
Gastroenterologist Dr. Mark Donowitz Pens Op-Ed on Challenges to Medical Research
AGA Urges Obama to Sign PDUFA Into Law